跳到正文
原文
Medical Xpress·· 15 天前精选AI 评分75

一个基因,两条路径:同一智力障碍相关基因的不同突变导致相反的突触缺陷

One gene, two paths: Opposite synaptic defects linked to same intellectual disability

AI 导读

研究团队发现同一基因的不同突变通过相反的突触机制导致类似的认知缺陷,强调个性化治疗策略的重要性。实验通过细胞模型和小鼠模型验证了不同突触机制的特定性,并探讨了临床药物对不同突变模型的治疗效果差异。

推荐理由

揭示了同一基因不同突变导致认知缺陷的相反机制,强调了个性化治疗的重要性。

正文
gene
Credit: Unsplash/CC0 Public Domain

A research team led by Dr. Sheng Nengyin of the Kunming Institute of Zoology (KIZ) of the Chinese Academy of Sciences has reframed ZC4H2-associated rare disorder (ZARD)—a disorder marked by intellectual disability, developmental delays, muscle weakness and other neurological or physical abnormalities—as a "disease spectrum" rather than a condition driven by a single mechanism.

Previously, the team demonstrated that ZC4H2 acts as a postsynaptic regulator of excitatory synaptic activity and brain cognition by modulating the protein stability of AMPA receptor subunits GluA1 and GluA2. However, it was unclear whether the same pathological mechanisms were at work in patients carrying different ZC4H2 variants, despite their clinical similarities.

Now, in more recent research, the team has shown that different pathogenic mutations in the same gene can produce nearly identical cognitive deficits through diametrically opposite synaptic mechanisms. The findings suggest that intervention should be guided by the specific mutation rather than the diagnosis alone.

The findings were published in Neuron on Nov. 5.

Similar deficits, opposite synaptic effects

In this new study, the team first expressed wild-type ZC4H2 and 23 pathogenic mutants in N2A cells. They identified two distinct classes: one that lost the ability to regulate excitatory AMPA receptor subunits GluA1/GluA2 (loss-of-function) and another that retained AMPA regulation but abnormally suppressed inhibitory GABAₐ receptor subunits α1/β1 (gain-of-function).

Electrophysiological recordings on hippocampal slices confirmed that the two classes specifically disrupted excitatory and inhibitory transmission, respectively.

To link mechanism to behavior, the researchers generated two knock-in mouse models carrying representative patient mutations: ZC4H2ᴸ⁶⁶ᴴ/ʸ and ZC4H2R²¹³ᵂ/ʸ. Both showed comparable cognitive deficits, including impaired novel-object recognition, social memory loss and defective spatial learning, without obvious motor or anxiety abnormalities.

However, their synaptic readouts pointed in opposite directions. ZC4H2ᴸ⁶⁶ᴴ/ʸ mice showed weakened GABAergic inhibitory transmission and impaired inhibitory long-term potentiation (LTP), while ZC4H2R²¹³ᵂ/ʸ mice showed heightened AMPAR-mediated excitatory transmission and impaired excitatory LTP.

Two distinct protein degradation pathways

Using TurboID proximity labeling, the team traced the divergence to two different E3 ubiquitin ligase pathways.

The L66H mutant developed a new interaction with makorin ring finger protein 2 (MKRN2), which promotes polyubiquitination and destabilization of GABAₐ receptor subunits. The R213W mutant, by contrast, disrupted ZC4H2's interaction with ring finger protein 220 (RNF220), reducing RNF220 stability and lowering ubiquitination of AMPA receptor subunits, leaving excitatory synapses overactive.

Genetic rescue experiments confirmed this specificity: Knockout of MKRN2 in forebrain excitatory neurons rescued only the L66H model, while expression of a degradation-resistant RNF220 variant rescued only the R213W model.

Drug responses depend on the mutation

The researchers also explored the therapeutic potential of two clinically used drugs. The GABAₐ agonist muscimol restored inhibitory transmission and cognition in ZC4H2ᴸ⁶⁶ᴴ/ʸ mice but had no effect in ZC4H2R²¹³ᵂ/ʸ mice, whereas the AMPAR antagonist perampanel produced the opposite result.

This contrasting response supports a mutation-stratified intervention strategy rather than a one-size-fits-all approach.

According to the researchers, the study's significance extends beyond ZARD. By demonstrating that phenotypic similarity can mask mechanistic opposition, it argues for incorporating molecular pathology—not just gene identity or clinical symptoms—into disease stratification for neurodevelopmental disorders.

In a field where more than 2,500 intellectual disability genes are known, the work offers a generalizable principle: Precision intervention requires matching the drug to the synaptic mechanism of the mutation.

Publication details

Opposing Excitatory and Inhibitory Synaptic Pathologies Drive ZC4H2-Associated Intellectual Disability, Neuron (2026). DOI: 10.1016/j.neuron.2026.10.008. www.cell.com/neuron/fulltext/S0896-6273(26)00778-6

Journal information: Neuron

Key medical concepts

AMPA receptor

Who's behind this story?

Swati Mestri

Swati Mestri

Swati Mestri holds a bachelor's degree in Electronics Engineering and has worked as a content editor since 2019. She has experience editing research documents across technology, health care, and materials science, and has a particular interest in technology and space. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: One gene, two paths: Opposite synaptic defects linked to same intellectual disability (2026, November 5) retrieved 5 November 2026 from https://medicalxpress.com/news/2026-11-gene-paths-synaptic-defects-linked.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com